Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: Results of St Jude NHL13 study

Leukemia

Volumn 23, Issue 6, 2009, Pages 1127-1130

  Sandlund, J T ^a   Pui, C H ^a   Zhou, Y ^a   Behm, F G ^a   Onciu, M ^a   Razzouk, B I ^a   Hijiya, N ^a   Campana, D ^a   Hudson, M M ^a   Ribeiro, R C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER STAGING; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FEMALE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOBLASTOMA; MAINTENANCE THERAPY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROLYMPHOCYTE; SALVAGE THERAPY; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; TYPHLITIS; UNITED STATES;

EID: 67349262358     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.400     Document Type: Article

References (24)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112-2135.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
3. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 2000; 95: 416-421.
4. Patte C, Kalifa C, Flamant F, Hartmann O, Brugieres L, Valteau-Couanet D et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992; 20: 105-113.
5. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 1999; 13: 335-342.
6. Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993; 11: 1024-1032.
7. Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: A Childrens Cancer Group study. J Clin Oncol 1995; 13: 1368-1376.
8. Weinstein HJ, Cassady JR, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983; 1: 537-541.
9. Dahl GV, Rivera G, Pui CH, Mirro Jr J, Ochs J, Kalwinsky DK et al. A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine. Blood 1985; 66: 1110-1114.
10. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334: 1238-1248.
11. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21: 3616-3622.
12. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24: 491-499.
13. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332-339.
14. Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer 1980; 45: 630-637.
15. Pui CH, Relling MV, Campana D, Evans WE. Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002; 6: 161-180; discussion 200-162.
16. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
17. Asselin BL, Shuster J, Amylon M, Halperin E, Hutchison R, Lipshultz S et al. Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): A Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 2001; 20: 367.
18. Edick MJ, Gajjar A, Mahmoud HH, van de Poll ME, Harrison PL, Panetta JC et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 1340-1346.
19. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351 550-554.
20. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273-279.
21. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review. Cancer 1997; 80: 1717-1726.
22. Sandlund JT, Harrison PL, Rivera G, Behm FG, Head D, Boyett J et al Persistence of lymphoblasts in bone marrow on day 15 and days 22-25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002; 100: 43-47.
23. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-58.
24. Coustan-Smith E, Abromowitz M, Sandlund JT, Campana D. A novel approach for minimal residual disease detection in childhood T-cell lymphoblastic lymphoma (T-LL): A Children's Oncology Group Report. Blood 2007; 110: 1042A-1043A.